Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- United States of America
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Mus musculus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Naive(Uninfected Untreated)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Tuberculosis + isoniazid-rifampin-pyrazinamide (HRZ) (TB +HRZ group) - 2weeks(W6)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Tuberculosis + isoniazid-rifampin-pyrazinamide (HRZ) (TB +HRZ group) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that started isoniazid-rifampin-pyrazinamide (HRZ) treatment two weeks after infection.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 3
- Group 1 sample size Number of subjects in the case (exposed) group
- 4
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 2weeks post infection.
Abundance in Group 1: increased abundance in Tuberculosis + isoniazid-rifampin-pyrazinamide (HRZ) (TB +HRZ group) - 2weeks(W6)
| NCBI | Quality Control | Links |
|---|---|---|
| Anaerorhabdus | ||
| Brenneria | ||
| Eggerthia | ||
| Tannerella | ||
| Thomasclavelia | ||
| Parabacteroides |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 2weeks post infection.
Abundance in Group 1: decreased abundance in Tuberculosis + isoniazid-rifampin-pyrazinamide (HRZ) (TB +HRZ group) - 2weeks(W6)
Revision editor(s): KateRasheed, WikiWorks
Experiment 2
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Naive
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 4weeks(W8)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 4weeks(W8) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that started isoniazid-rifampin-pyrazinamide (HRZ) treatment four weeks after infection.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 4weeks post infection.
Abundance in Group 1: increased abundance in TB +HRZ group - 4weeks(W8)
| NCBI | Quality Control | Links |
|---|---|---|
| Alistipes | ||
| Anaerorhabdus | ||
| Anaerosporobacter | ||
| Barnesiella | ||
| Bifidobacterium | ||
| Brenneria | ||
| Eggerthia | ||
| Mucispirillum | ||
| Oxobacter | ||
| Thomasclavelia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 4weeks post infection.
Abundance in Group 1: decreased abundance in TB +HRZ group - 4weeks(W8)
Revision editor(s): KateRasheed, WikiWorks
Experiment 3
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 2months into HR therapy(W12)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 2months into HR therapy(W12) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that are two months into H-Isoniazid; R-Rifampin(HR) therapy.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 2months into anti-tuberculosis HR(H-Isoniazid, R-Rifampin) therapy.
Abundance in Group 1: increased abundance in TB +HRZ group - 2months into HR therapy(W12)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 2months into anti-tuberculosis HR(H-Isoniazid, R-Rifampin) therapy.
Abundance in Group 1: decreased abundance in TB +HRZ group - 2months into HR therapy(W12)
Revision editor(s): KateRasheed, WikiWorks
Experiment 4
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 3months HR(W16)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 3months into HR therapy(W16) refers to the first time point of stool collection (W16) following the switch in the antibiotic regimen from triple HRZ to double HR administration.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 3months into anti-tuberculosis HR(H-Isoniazid, R-Rifampin) therapy.
Abundance in Group 1: increased abundance in TB +HRZ group - 3months HR(W16)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 3months into anti-tuberculosis HR(H-Isoniazid, R-Rifampin) therapy.
Abundance in Group 1: decreased abundance in TB +HRZ group - 3months HR(W16)
Revision editor(s): KateRasheed, WikiWorks
Experiment 5
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 4months HR(W20)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 4months into HR therapy(W20) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that are four months into HR therapy. This is also referred to as the termination of HR therapy
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 4months into anti-tuberculosis HR therapy(end of therapy).
Abundance in Group 1: increased abundance in TB +HRZ group - 4months HR(W20)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 4: Figure S4
Description: Differentially abundant bacterial taxa between the naive and TB + HRZ groups at 4months into anti-tuberculosis HR therapy(end of therapy).
Abundance in Group 1: decreased abundance in TB +HRZ group - 4months HR(W20)
Revision editor(s): KateRasheed, WikiWorks
Experiment 6
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Untreated Tuberculosis group(TB)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 2weeks(W6)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 2weeks(W6) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that started isoniazid-rifampin-pyrazinamide (HRZ) treatment two weeks after infection.
Lab analysis
Statistical Analysis
- Matched on Factors on which subjects have been matched on in a case-control study
- Not specified
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 2weeks post infection.
Abundance in Group 1: increased abundance in TB +HRZ group - 2weeks(W6)
| NCBI | Quality Control | Links |
|---|---|---|
| Tannerella | ||
| Erysipelotrichaceae | ||
| Anaerorhabdus | ||
| Thomasclavelia | ||
| Anaerosporobacter | ||
| Eggerthia | ||
| Anaeroplasma | ||
| Brenneria | ||
| Prolixibacter |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 2weeks post infection.
Abundance in Group 1: decreased abundance in TB +HRZ group - 2weeks(W6)
Revision editor(s): KateRasheed, WikiWorks
Experiment 7
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 4weeks(W8)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 4weeks(W8) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that started isoniazid-rifampin-pyrazinamide (HRZ) treatment four weeks after infection.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 5: Figure S5
Description: Differentially abundant bacterial taxa between the TB and TB + HRZ groups at 4weeks post infection.
Abundance in Group 1: increased abundance in TB +HRZ group - 4weeks(W8)
| NCBI | Quality Control | Links |
|---|---|---|
| Barnesiella | ||
| Anaerorhabdus | ||
| Eggerthia | ||
| Alistipes | ||
| Bifidobacterium | ||
| Thomasclavelia | ||
| Oxobacter | ||
| Brenneria | ||
| Anaerosporobacter | ||
| Gordonibacter | ||
| Anaeroplasma |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 5: Figure S5
Description: Differentially abundant bacterial taxa between the TB and TB + HRZ groups at 4weeks post infection.
Abundance in Group 1: decreased abundance in TB +HRZ group - 4weeks(W8)
Revision editor(s): KateRasheed, WikiWorks
Experiment 8
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 2months into HR therapy(W12)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 2months into HR therapy(W12) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that are two months into H-Isoniazid; R-Rifampin(HR) therapy.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 2months HR therapy.
Abundance in Group 1: increased abundance in TB +HRZ group - 2months into HR therapy(W12)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 2months HR therapy.
Abundance in Group 1: decreased abundance in TB +HRZ group - 2months into HR therapy(W12)
Revision editor(s): KateRasheed, WikiWorks
Experiment 9
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 3months HR(W16)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 3months into HR therapy(W16) refers to the first time point of stool collection (W16) following the switch in the antibiotic regimen from triple HRZ to double HR administration.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 3months HR therapy.
Abundance in Group 1: increased abundance in TB +HRZ group - 3months HR(W16)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 3months HR therapy.
Abundance in Group 1: decreased abundance in TB +HRZ group - 3months HR(W16)
Revision editor(s): KateRasheed, WikiWorks
Experiment 10
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ group - 4months HR(W20)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ group - 4months into HR therapy(W20) refers to the group of mice infected with Mycobacterium tuberculosis (H37Rv) by aerosol inhalation, that are four months into HR therapy. This is also referred to as the termination of HR therapy.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 4months HR therapy(termination of therapy).
Abundance in Group 1: increased abundance in TB +HRZ group - 4months HR(W20)
| NCBI | Quality Control | Links |
|---|---|---|
| Porphyromonas | ||
| Anaerorhabdus | ||
| Tannerella | ||
| Paraprevotella | ||
| Parasutterella | ||
| Enterococcus | ||
| Akkermansia | ||
| Thomasclavelia | ||
| Olsenella | ||
| Eggerthia | ||
| Bifidobacterium | ||
| Christensenella |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 5: Figure S5
Description: Differentially abundant taxa between the TB and TB + HRZ groups at 4months HR therapy(termination of therapy).
Abundance in Group 1: decreased abundance in TB +HRZ group - 4months HR(W20)
Revision editor(s): KateRasheed, WikiWorks
Experiment 11
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Tuberculosis group(TB)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ groups (all time points:M2-M5)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ groups (all time points:M2-M5) refers to the months (M) of stool sample collection relative to the date of infection rather than treatment. C57BL/6J female mice were used and treatment was terminated at month 5 of Mtb infection.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 4
Lab analysis
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.01
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 6: Figure S6
Description: Differentially abundant taxa between the TB and TB + HRZ groups at all timepoints (months of infection).
Abundance in Group 1: increased abundance in TB +HRZ groups (all time points:M2-M5)
| NCBI | Quality Control | Links |
|---|---|---|
| Christensenella | ||
| Enterorhabdus | ||
| Salimesophilobacter | ||
| Thomasclavelia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 6: Figure S6
Description: Differentially abundant taxa between the TB and TB + HRZ groups at all timepoints (months of infection).
Abundance in Group 1: decreased abundance in TB +HRZ groups (all time points:M2-M5)
Revision editor(s): KateRasheed, WikiWorks
Experiment 12
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Untreated Tuberculosis group(TB)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB +HRZ groups (all time points:M2-M7)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB +HRZ groups (all time points:M2-M7) refers to the months (M) of stool sample collection relative to the date of infection rather than treatment. C57BL/6J-CD45a(Ly5a) female mice were used and treatment was terminated at month 7 of Mtb infection.
- Group 0 sample size Number of subjects in the control (unexposed) group
- Not specified
- Group 1 sample size Number of subjects in the case (exposed) group
- Not specified
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 7: Figure S7
Description: Differentially abundant taxa between the TB and TB + HRZ groups at all timepoints (months of infection). Treatment was terminated at M7.
Abundance in Group 1: increased abundance in TB +HRZ groups (all time points:M2-M7)
| NCBI | Quality Control | Links |
|---|---|---|
| Eggerthia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 7: Figure S7
Description: Differentially abundant taxa between the TB and TB + HRZ groups at all timepoints (months of infection). Treatment was terminated at M7.
Abundance in Group 1: decreased abundance in TB +HRZ groups (all time points:M2-M7)
| NCBI | Quality Control | Links |
|---|---|---|
| Acetanaerobacterium | ||
| Acidaminobacter | ||
| Anaerovorax | ||
| Clostridium | ||
| Erysipelotrichaceae | ||
| Eubacteriales Family XII. Incertae Sedis | ||
| Oxobacter | ||
| Solitalea | ||
| Turicibacter | ||
| Pelotomaculum |
Revision editor(s): KateRasheed, WikiWorks
Experiment 13
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- TB + HRZ (W4 to W20)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Post HRZ (W24 to W32)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Post HRZ (W24 to W32) refers to stool samples at monthly intervals for 3 months’ post cessation of therapy.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 24
- Group 1 sample size Number of subjects in the case (exposed) group
- 12
Lab analysis
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 8: Figure S8
Description: Differentially abundant taxa between the TB + HRZ and post HRZ groups.
Abundance in Group 1: increased abundance in Post HRZ (W24 to W32)
| NCBI | Quality Control | Links |
|---|---|---|
| Romboutsia | ||
| Stomatobaculum |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 8: Figure S8
Description: Differentially abundant taxa between the TB + HRZ and post HRZ groups.
Abundance in Group 1: decreased abundance in Post HRZ (W24 to W32)
| NCBI | Quality Control | Links |
|---|---|---|
| Lactobacillus | ||
| Brenneria |
Revision editor(s): KateRasheed, WikiWorks
Experiment 14
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Naive
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- TB + HRZ groups (W4-W20 time points)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- TB + HRZ groups refers to all timepoints of anti-tuberculosis treatment, that is, from day 1(W4) to the termination of therapy(W20).
- Group 0 sample size Number of subjects in the control (unexposed) group
- Not specified
- Group 1 sample size Number of subjects in the case (exposed) group
- Not specified
Lab analysis
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.01
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Fig. 3C
Description: Differentially abundant taxa between the naïve and TB + HRZ groups from day 1(W4) to the termination of therapy(W20).
Abundance in Group 1: increased abundance in TB + HRZ groups (W4-W20 time points)
| NCBI | Quality Control | Links |
|---|---|---|
| Thomasclavelia | ||
| Eggerthia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Fig. 3C
Description: Differentially abundant taxa between the naïve and TB + HRZ groups from day 1(W4) to the termination of therapy(W20).
Abundance in Group 1: decreased abundance in TB + HRZ groups (W4-W20 time points)
Revision editor(s): KateRasheed, WikiWorks
Experiment 15
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Untreated Tuberculosis group(TB)
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Fig. 3D
Description: Differentially abundant taxa between the naïve and TB + HRZ groups from day 1(W4) to the termination of therapy(W20).
Abundance in Group 1: increased abundance in TB + HRZ groups (W4-W20 time points)
| NCBI | Quality Control | Links |
|---|---|---|
| Thomasclavelia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Fig. 3D
Description: Differentially abundant taxa between the naïve and TB + HRZ groups from day 1(W4) to the termination of therapy(W20).
Abundance in Group 1: decreased abundance in TB + HRZ groups (W4-W20 time points)
| NCBI | Quality Control | Links |
|---|---|---|
| Acetivibrio | ||
| Robinsoniella | ||
| Alkaliphilus | ||
| Stomatobaculum | ||
| Butyricicoccus | ||
| Acetanaerobacterium | ||
| Tyzzerella | ||
| Ruminococcus | ||
| Peptococcus |
Revision editor(s): KateRasheed, WikiWorks
Experiment 16
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Naive
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Post HRZ (W24 to W32)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Post HRZ (W24 to W32) refers to stool samples at monthly intervals for 3 months’ post cessation of therapy.
Lab analysis
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Fig. 5E
Description: Differentially abundant genera between the naïve and post HRZ groups (W24–W32).
Abundance in Group 1: increased abundance in Post HRZ (W24 to W32)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Fig. 5E
Description: Differentially abundant genera between the naïve and post HRZ groups (W24–W32).
Abundance in Group 1: decreased abundance in Post HRZ (W24 to W32)
Revision editor(s): KateRasheed, WikiWorks
Experiment 17
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- H (Isoniazid)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- H (Isoniazid) refers to Isoniazid treatment given to the uninfected and 4-week Mtb-infected mice.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 3
- Group 1 sample size Number of subjects in the case (exposed) group
- 4
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and Isoniazid treatment group.
Abundance in Group 1: increased abundance in H (Isoniazid)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and Isoniazid treatment group.
Abundance in Group 1: decreased abundance in H (Isoniazid)
| NCBI | Quality Control | Links |
|---|---|---|
| Arthrobacter | ||
| Dorea | ||
| Turicibacter | ||
| Oxobacter | ||
| Clostridium | ||
| Pelotomaculum | ||
| Akkermansia | ||
| Tannerella |
Revision editor(s): KateRasheed, WikiWorks
Experiment 18
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- R (Rifampin)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- R (Rifampin) refers to Rifampin treatment given to the uninfected and 4-week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 11: Figure S11.
Description: Differentially abundant between the Naive group and Rifampin treatment group.
Abundance in Group 1: increased abundance in R (Rifampin)
| NCBI | Quality Control | Links |
|---|---|---|
| Erysipelothrix | ||
| Mucispirillum | ||
| Anaerosporobacter | ||
| Marvinbryantia | ||
| Anaerostipes | ||
| Gordonibacter | ||
| Caloramator | ||
| Enterorhabdus |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and Rifampin treatment group.
Abundance in Group 1: decreased abundance in R (Rifampin)
Revision editor(s): KateRasheed, WikiWorks
Experiment 19
Curated date: 2024/11/10
Curator:
Revision editor(s):
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Z (Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Z (Pyrazinamide) refers to Pyrazinamide treatment given to uninfected and 4-week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and Pyrazinamide treatment group.
Abundance in Group 1: increased abundance in
| NCBI | Quality Control | Links |
|---|---|---|
| Marvinbryantia | ||
| Anaeroplasma | ||
| Erysipelothrix |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and Pyrazinamide treatment group.
Abundance in Group 1: decreased abundance in
| NCBI | Quality Control | Links |
|---|---|---|
| Thomasclavelia | ||
| Sporobacter | ||
| Arthrobacter | ||
| Akkermansia |
Revision editor(s): KateRasheed, WikiWorks
Experiment 20
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- HR (H-Isoniazid, R-Rifampin)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- HR (H-Isoniazid, R-Rifampin) refers to the Isoniazid and Rifampin treatment given to uninfected and 4week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and HR (H-Isoniazid, R-Rifampin) treatment group.
Abundance in Group 1: increased abundance in HR (H-Isoniazid, R-Rifampin)
| NCBI | Quality Control | Links |
|---|---|---|
| Tannerella | ||
| Parabacteroides | ||
| Brenneria | ||
| Erysipelothrix | ||
| Anaeroplasma | ||
| Anaerostipes |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and HR (H-Isoniazid, R-Rifampin) treatment group.
Abundance in Group 1: decreased abundance in HR (H-Isoniazid, R-Rifampin)
Revision editor(s): KateRasheed, WikiWorks
Experiment 21
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- HZ (H-Isoniazid, Z-Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- HZ (H-Isoniazid, Z-Pyrazinamide) refers to the Isoniazid and Pyrazinamide treatment given to uninfected and 4week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and HZ (H-Isoniazid, Z-Pyrazinamide) treatment group.
Abundance in Group 1: increased abundance in HZ (H-Isoniazid, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Barnesiella | ||
| Dysgonomonas | ||
| Shewanella | ||
| Gordonibacter | ||
| Marvinbryantia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and HZ (H-Isoniazid, Z-Pyrazinamide) treatment group.
Abundance in Group 1: decreased abundance in HZ (H-Isoniazid, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Eubacteriales Family XIII. Incertae Sedis | ||
| Guggenheimella | ||
| Arthrobacter | ||
| Ruminococcus | ||
| Clostridium | ||
| Sporobacter | ||
| Coprobacter | ||
| Akkermansia |
Revision editor(s): KateRasheed, WikiWorks
Experiment 22
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- RZ (R-Rifampin, Z-Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- RZ (R-Rifampin, Z-Pyrazinamide) refers to the Rifampin and Pyrazinamide treatment given to uninfected and 4week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and RZ (R-Rifampin, Z-Pyrazinamide) treatment group.
Abundance in Group 1: increased abundance in RZ (R-Rifampin, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides | ||
| Blautia | ||
| Brenneria | ||
| Anaeroplasma | ||
| Anaerostipes | ||
| Thomasclavelia |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant between the Naive group and RZ (R-Rifampin, Z-Pyrazinamide) treatment group.
Abundance in Group 1: decreased abundance in RZ (R-Rifampin, Z-Pyrazinamide)
Revision editor(s): KateRasheed, WikiWorks
Experiment 23
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide) refers to the Isoniazid, Rifampin and Pyrazinamide treatment given to uninfected and 4week Mtb-infected mice.
- Group 1 sample size Number of subjects in the case (exposed) group
- 3
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 11: Figure S11
Description: Differentially abundant taxa between the Naive group and HRZ (H-Isoniazid, R-Rifampin, Z-Pyrazinamide) treatment group.
Abundance in Group 1: increased abundance in HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 11: Figure S11
Description: Differentially abundant taxa between the Naive group and HRZ (H-Isoniazid, R-Rifampin, Z-Pyrazinamide) treatment group.
Abundance in Group 1: decreased abundance in HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide)
Revision editor(s): KateRasheed, WikiWorks
Experiment 24
Curated date: 2024/11/11
Curator:
Revision editor(s):
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- VANM(uninfected mice receiving vanomycin, ampicillin, neomycin, and metronidazole)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- H (Isoniazid)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- H (Isoniazid) refers to Isoniazid treatment given to the uninfected and 4-week Mtb-infected mice.
- Group 1 sample size Number of subjects in the case (exposed) group
- 4
Lab analysis
Statistical Analysis
- Matched on Factors on which subjects have been matched on in a case-control study
- Not specified
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Isoniazid treatment group.
Abundance in Group 1: increased abundance in
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Isoniazid treatment group.
Abundance in Group 1: decreased abundance in
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Eubacteriales Family XIII. Incertae Sedis |
Revision editor(s): KateRasheed, WikiWorks
Experiment 25
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- R (Rifampin)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- R (Rifampin) refers to Rifampin treatment given to the uninfected and 4-week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Rifampin treatment group.
Abundance in Group 1: increased abundance in R (Rifampin)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Rifampin treatment group.
Abundance in Group 1: decreased abundance in R (Rifampin)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Eubacteriales Family XIII. Incertae Sedis | ||
| Alistipes | ||
| Salimesophilobacter |
Revision editor(s): KateRasheed, WikiWorks
Experiment 26
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Z (Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Z (Pyrazinamide) refers to Pyrazinamide treatment given to uninfected and 4-week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Pyrazinamide treatment group.
Abundance in Group 1: increased abundance in Z (Pyrazinamide)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Pyrazinamide treatment group.
Abundance in Group 1: decreased abundance in Z (Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Thomasclavelia | ||
| Eubacteriales Family XIII. Incertae Sedis |
Revision editor(s): KateRasheed, WikiWorks
Experiment 27
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- HR (H-Isoniazid, R-Rifampin)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- HR (H-Isoniazid, R-Rifampin) refers to the Isoniazid and Rifampin treatment given to uninfected and 4week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and HR (H-Isoniazid, R-Rifampin) treatment group.
Abundance in Group 1: increased abundance in HR (H-Isoniazid, R-Rifampin)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and HR (H-Isoniazid, R-Rifampin) treatment group.
Abundance in Group 1: decreased abundance in HR (H-Isoniazid, R-Rifampin)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Lactobacillus | ||
| Eubacteriales Family XIII. Incertae Sedis | ||
| Salimesophilobacter |
Revision editor(s): KateRasheed, WikiWorks
Experiment 28
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- HZ (H-Isoniazid, Z-Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- HZ (H-Isoniazid, Z-Pyrazinamide) refers to the Isoniazid and Pyrazinamide treatment given to uninfected and 4week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and HZ
Abundance in Group 1: increased abundance in HZ (H-Isoniazid, Z-Pyrazinamide)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and HZ treatment group.
Abundance in Group 1: decreased abundance in HZ (H-Isoniazid, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Eubacteriales Family XIII. Incertae Sedis |
Revision editor(s): KateRasheed, WikiWorks
Experiment 29
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- RZ (R-Rifampin, Z-Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- RZ (R-Rifampin, Z-Pyrazinamide) refers to the Rifampin and Pyrazinamide treatment given to uninfected and 4week Mtb-infected mice.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and RZ treatment group.
Abundance in Group 1: increased abundance in RZ (R-Rifampin, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Eubacterium | ||
| Erysipelotrichaceae | ||
| Thomasclavelia | ||
| Anaeroplasma | ||
| Anaerostipes | ||
| Blautia | ||
| Akkermansia | ||
| Alistipes | ||
| Tannerella | ||
| Bacteroides |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and RZ treatment group.
Abundance in Group 1: decreased abundance in RZ (R-Rifampin, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Eubacteriales Family XIII. Incertae Sedis | ||
| Lactobacillus |
Revision editor(s): KateRasheed, WikiWorks
Experiment 30
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide) refers to the Isoniazid, Rifampin and Pyrazinamide treatment given to uninfected and 4week Mtb-infected mice.
- Group 1 sample size Number of subjects in the case (exposed) group
- 3
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Chao1 Abundance-based estimator of species richness
- increased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and HRZ (H-Isoniazid, R-Rifampin, Z-Pyrazinamide) treatment group.
Abundance in Group 1: increased abundance in HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide)
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and HRZ (H-Isoniazid, R-Rifampin, Z-Pyrazinamide) treatment group.
Abundance in Group 1: decreased abundance in HRZ(H-Isoniazid, R-Rifampin, Z-Pyrazinamide)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Lactobacillus | ||
| Eubacteriales Family XIII. Incertae Sedis |
Revision editor(s): KateRasheed, WikiWorks
Experiment 31
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Naive(Uninfected Untreated)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- VANM(uninfected mice receiving vanomycin, ampicillin, neomycin, and metronidazole)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- VANM refers to the uninfected mice receiving vanomycin, ampicillin, neomycin, and metronidazole.
Lab analysis
Statistical Analysis
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
Signature 1
Source: Additional file 12: Figure S12
Description: Differentially abundant taxa between the VANM group and Naive(untreated uninfected) group.
Abundance in Group 1: increased abundance in VANM(uninfected mice receiving vanomycin, ampicillin, neomycin, and metronidazole)
| NCBI | Quality Control | Links |
|---|---|---|
| Parabacteroides | ||
| Brenneria | ||
| Ruminiclostridium | ||
| Eubacteriales Family XIII. Incertae Sedis |
Revision editor(s): KateRasheed, WikiWorks
Signature 2
Source: Additional file 12: Figure S12
Description:
Abundance in Group 1: decreased abundance in VANM(uninfected mice receiving vanomycin, ampicillin, neomycin, and metronidazole)
Revision editor(s): KateRasheed, WikiWorks
Contents
- 1 Experiment 1
- 2 Experiment 2
- 3 Experiment 3
- 4 Experiment 4
- 5 Experiment 5
- 6 Experiment 6
- 7 Experiment 7
- 8 Experiment 8
- 9 Experiment 9
- 10 Experiment 10
- 11 Experiment 11
- 12 Experiment 12
- 13 Experiment 13
- 14 Experiment 14
- 15 Experiment 15
- 16 Experiment 16
- 17 Experiment 17
- 18 Experiment 18
- 19 Experiment 19
- 20 Experiment 20
- 21 Experiment 21
- 22 Experiment 22
- 23 Experiment 23
- 24 Experiment 24
- 25 Experiment 25
- 26 Experiment 26
- 27 Experiment 27
- 28 Experiment 28
- 29 Experiment 29
- 30 Experiment 30
- 31 Experiment 31
